Glynn Capital Management LLC Decreases Stake in Merck & Co., Inc. $MRK

Glynn Capital Management LLC cut its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 10.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,701 shares of the company’s stock after selling 1,500 shares during the period. Glynn Capital Management LLC’s holdings in Merck & Co., Inc. were worth $1,005,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of MRK. Legend Financial Advisors Inc. acquired a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at approximately $25,000. CBIZ Investment Advisory Services LLC grew its position in shares of Merck & Co., Inc. by 141.7% during the first quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock worth $34,000 after buying an additional 221 shares in the last quarter. Fiduciary Wealth Partners LLC bought a new stake in shares of Merck & Co., Inc. in the first quarter worth $48,000. MJT & Associates Financial Advisory Group Inc. acquired a new stake in Merck & Co., Inc. in the first quarter valued at $48,000. Finally, Mountain Hill Investment Partners Corp. bought a new position in Merck & Co., Inc. during the 2nd quarter valued at $43,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $90.91 on Wednesday. The company has a market cap of $225.64 billion, a P/E ratio of 14.01, a PEG ratio of 0.95 and a beta of 0.34. The business has a 50 day moving average of $84.76 and a two-hundred day moving average of $82.19. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $105.07. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Thursday, October 30th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.36 by $0.22. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The business had revenue of $17.28 billion for the quarter, compared to the consensus estimate of $17 billion. During the same quarter last year, the business posted $1.57 EPS. The business’s revenue was up 3.7% on a year-over-year basis. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP David Michael Williams sold 8,614 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $83.59, for a total value of $720,044.26. Following the sale, the executive vice president directly owned 24,578 shares in the company, valued at approximately $2,054,475.02. This trade represents a 25.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.13% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Berenberg Bank lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their price objective for the company from $100.00 to $90.00 in a report on Wednesday, September 17th. Citigroup assumed coverage on Merck & Co., Inc. in a research note on Monday, October 13th. They set a “neutral” rating and a $95.00 price objective on the stock. Morgan Stanley lifted their target price on Merck & Co., Inc. from $98.00 to $100.00 and gave the stock an “equal weight” rating in a research report on Monday, November 3rd. Finally, Wells Fargo & Company dropped their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $104.47.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.